NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Damora Therapeutics, Inc. (DMRA) Stock Analysis

Damora Therapeutics, Inc. (DMRA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

DMRA

$30.06

+$2.06 (+7.36%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare DMRA with… →

DMRA Key Statistics

As of Sep 4, 2026
Trading
Open
$27.49
Previous Close
$28.00
Day's Range
27.39–30.35
52-Week Range
2.45–38.33
Volume
295.80K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.47
Valuation
Market Cap
$1.86B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.28
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$209.84M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
61.74M
1-Year Return
+902.00%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
569.67K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

DMRA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+30.64%
2025+394.84%
2024−74.17%
2023−37.39%
2022−62.05%
2021−75.78%
2020 (partial year)−16.60%

As of September 4, 2026.

DMRA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$209.84M—
2024$0.00−$21.44M—
2023$0.00−$38.35M—
2022$0.00−$61.62M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$210.87M−$209.84M—
2024$0.00—−$21.29M−$21.44M—
2023$0.00—−$36.46M−$38.35M—
2022$0.00—−$61.21M−$61.62M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

DMRA Valuation vs Biotechnology Median

Median of 656 stocks
MetricDMRABiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 8 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Damora Therapeutics, Inc. (DMRA) is capitalised at $1.86B on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 7.

Over the past 52 weeks the price has ranged from $2.45 to $38.33. The most recent close on file for DMRA is $30.06, dated September 4, 2026. That is +$2.06 (+7.36%) against the previous close. The latest close sits 1,126.94% above that 52-week low.

Financial Health

In fiscal 2025, Damora Therapeutics, Inc. reported revenue of $0.00. The same year closed with a net loss of $209.84M. Profit margin runs at 0%. Trailing earnings per share are −0.28.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The reported beta is 1.47. Annualized volatility over the trailing 5 years is 229.77%. The trailing one-year price return is +902.00%. Across 5 years the annualized return works out at −22.89%.

Growth & Income

The record shows no dividend for DMRA.

2026 is still running; the price is +30.64% year to date. Across the complete calendar years on file, 2025 returned +394.84% and 2021 returned −75.78%. Of the 5 complete calendar years on file, 1 finished higher.

Peer Comparison

Damora Therapeutics, Inc. (DMRA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Damora Therapeutics, Inc. DMRA $1.86B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Damora Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Damora Therapeutics, Inc.

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.

Visit website →